vs
EXACT SCIENCES CORP（EXAS）与NetApp（NTAP）财务数据对比。点击上方公司名可切换其他公司
NetApp的季度营收约是EXACT SCIENCES CORP的2.0倍（$1.7B vs $878.4M），NetApp净利率更高（19.5% vs -9.8%，领先29.3%），EXACT SCIENCES CORP同比增速更快（23.1% vs 4.4%），NetApp自由现金流更多（$271.0M vs $120.4M），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs 1.3%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
NetApp是总部位于美国加利福尼亚州圣何塞的企业级数据基础设施服务商，成立于1992年，2012至2021年连续入选《财富》世界500强。公司面向全球企业客户提供统一数据存储、集成数据服务及云运营解决方案，可满足线上线下全场景的应用与数据管理需求。
EXAS vs NTAP — 直观对比
营收规模更大
NTAP
是对方的2.0倍
$878.4M
营收增速更快
EXAS
高出18.7%
4.4%
净利率更高
NTAP
高出29.3%
-9.8%
自由现金流更多
NTAP
多$150.6M
$120.4M
两年增速更快
EXAS
近两年复合增速
1.3%
损益表 — Q4 FY2025 vs Q4 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $1.7B |
| 净利润 | $-86.0M | $334.0M |
| 毛利率 | 70.1% | 70.6% |
| 营业利润率 | -9.4% | 25.3% |
| 净利率 | -9.8% | 19.5% |
| 营收同比 | 23.1% | 4.4% |
| 净利润同比 | 90.1% | 11.7% |
| 每股收益（稀释后） | $-0.45 | $1.67 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASNTAP
| Q1 26 | — | $1.7B | ||
| Q4 25 | $878.4M | $1.7B | ||
| Q3 25 | $850.7M | $1.6B | ||
| Q2 25 | $811.1M | $1.7B | ||
| Q1 25 | $706.8M | $1.6B | ||
| Q4 24 | $713.4M | $1.7B | ||
| Q3 24 | $708.7M | $1.5B | ||
| Q2 24 | $699.3M | $1.7B |
净利润EXASNTAP
| Q1 26 | — | $334.0M | ||
| Q4 25 | $-86.0M | $305.0M | ||
| Q3 25 | $-19.6M | $233.0M | ||
| Q2 25 | $-1.2M | $340.0M | ||
| Q1 25 | $-101.2M | $299.0M | ||
| Q4 24 | $-864.6M | $299.0M | ||
| Q3 24 | $-38.2M | $248.0M | ||
| Q2 24 | $-15.8M | $291.0M |
毛利率EXASNTAP
| Q1 26 | — | 70.6% | ||
| Q4 25 | 70.1% | 72.0% | ||
| Q3 25 | 68.6% | 70.4% | ||
| Q2 25 | 69.3% | 68.9% | ||
| Q1 25 | 70.8% | 69.8% | ||
| Q4 24 | 69.0% | 71.0% | ||
| Q3 24 | 69.4% | 71.3% | ||
| Q2 24 | 69.8% | 70.5% |
营业利润率EXASNTAP
| Q1 26 | — | 25.3% | ||
| Q4 25 | -9.4% | 23.4% | ||
| Q3 25 | -3.0% | 19.8% | ||
| Q2 25 | -0.3% | 20.1% | ||
| Q1 25 | -13.6% | 22.1% | ||
| Q4 24 | -122.8% | 20.8% | ||
| Q3 24 | -5.6% | 18.3% | ||
| Q2 24 | -3.8% | 21.9% |
净利率EXASNTAP
| Q1 26 | — | 19.5% | ||
| Q4 25 | -9.8% | 17.9% | ||
| Q3 25 | -2.3% | 14.9% | ||
| Q2 25 | -0.1% | 19.6% | ||
| Q1 25 | -14.3% | 18.2% | ||
| Q4 24 | -121.2% | 18.0% | ||
| Q3 24 | -5.4% | 16.1% | ||
| Q2 24 | -2.3% | 17.4% |
每股收益（稀释后）EXASNTAP
| Q1 26 | — | $1.67 | ||
| Q4 25 | $-0.45 | $1.51 | ||
| Q3 25 | $-0.10 | $1.15 | ||
| Q2 25 | $-0.01 | $1.64 | ||
| Q1 25 | $-0.54 | $1.44 | ||
| Q4 24 | $-4.69 | $1.42 | ||
| Q3 24 | $-0.21 | $1.17 | ||
| Q2 24 | $-0.09 | $1.36 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $3.0B |
| 总债务越低越好 | — | $2.5B |
| 股东权益账面价值 | $2.4B | $1.2B |
| 总资产 | $5.9B | $10.0B |
| 负债/权益比越低杠杆越低 | — | 2.15× |
8季度趋势，按日历期对齐
现金及短期投资EXASNTAP
| Q1 26 | — | $3.0B | ||
| Q4 25 | $964.7M | $3.0B | ||
| Q3 25 | $1.0B | $3.3B | ||
| Q2 25 | $858.4M | $3.8B | ||
| Q1 25 | $786.2M | $2.3B | ||
| Q4 24 | $1.0B | $2.2B | ||
| Q3 24 | $1.0B | $3.0B | ||
| Q2 24 | $946.8M | $3.3B |
总债务EXASNTAP
| Q1 26 | — | $2.5B | ||
| Q4 25 | — | $2.5B | ||
| Q3 25 | — | $2.5B | ||
| Q2 25 | — | $3.2B | ||
| Q1 25 | — | $2.0B | ||
| Q4 24 | — | $2.0B | ||
| Q3 24 | — | $2.4B | ||
| Q2 24 | — | $2.4B |
股东权益EXASNTAP
| Q1 26 | — | $1.2B | ||
| Q4 25 | $2.4B | $986.0M | ||
| Q3 25 | $2.5B | $975.0M | ||
| Q2 25 | $2.5B | $1.0B | ||
| Q1 25 | $2.4B | $995.0M | ||
| Q4 24 | $2.4B | $892.0M | ||
| Q3 24 | $3.2B | $929.0M | ||
| Q2 24 | $3.2B | $1.1B |
总资产EXASNTAP
| Q1 26 | — | $10.0B | ||
| Q4 25 | $5.9B | $9.6B | ||
| Q3 25 | $5.9B | $9.7B | ||
| Q2 25 | $5.8B | $10.8B | ||
| Q1 25 | $5.7B | $9.0B | ||
| Q4 24 | $5.9B | $9.0B | ||
| Q3 24 | $6.7B | $9.3B | ||
| Q2 24 | $6.7B | $9.9B |
负债/权益比EXASNTAP
| Q1 26 | — | 2.15× | ||
| Q4 25 | — | 2.52× | ||
| Q3 25 | — | 2.55× | ||
| Q2 25 | — | 3.11× | ||
| Q1 25 | — | 2.00× | ||
| Q4 24 | — | 2.23× | ||
| Q3 24 | — | 2.58× | ||
| Q2 24 | — | 2.09× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $317.0M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $271.0M |
| 自由现金流率自由现金流/营收 | 13.7% | 15.8% |
| 资本支出强度资本支出/营收 | 3.6% | — |
| 现金转化率经营现金流/净利润 | — | 0.95× |
| 过去12个月自由现金流最近4个季度 | $356.8M | — |
8季度趋势，按日历期对齐
经营现金流EXASNTAP
| Q1 26 | — | $317.0M | ||
| Q4 25 | $151.7M | $127.0M | ||
| Q3 25 | $219.9M | $673.0M | ||
| Q2 25 | $89.0M | — | ||
| Q1 25 | $30.8M | $385.0M | ||
| Q4 24 | $47.1M | — | ||
| Q3 24 | $138.7M | $341.0M | ||
| Q2 24 | $107.1M | $613.0M |
自由现金流EXASNTAP
| Q1 26 | — | $271.0M | ||
| Q4 25 | $120.4M | $78.0M | ||
| Q3 25 | $190.0M | $620.0M | ||
| Q2 25 | $46.7M | — | ||
| Q1 25 | $-365.0K | $338.0M | ||
| Q4 24 | $10.7M | — | ||
| Q3 24 | $112.6M | $300.0M | ||
| Q2 24 | $71.2M | $567.0M |
自由现金流率EXASNTAP
| Q1 26 | — | 15.8% | ||
| Q4 25 | 13.7% | 4.6% | ||
| Q3 25 | 22.3% | 39.8% | ||
| Q2 25 | 5.8% | — | ||
| Q1 25 | -0.1% | 20.6% | ||
| Q4 24 | 1.5% | — | ||
| Q3 24 | 15.9% | 19.5% | ||
| Q2 24 | 10.2% | 34.0% |
资本支出强度EXASNTAP
| Q1 26 | — | — | ||
| Q4 25 | 3.6% | 2.9% | ||
| Q3 25 | 3.5% | 3.4% | ||
| Q2 25 | 5.2% | — | ||
| Q1 25 | 4.4% | 2.9% | ||
| Q4 24 | 5.1% | — | ||
| Q3 24 | 3.7% | 2.7% | ||
| Q2 24 | 5.1% | 2.8% |
现金转化率EXASNTAP
| Q1 26 | — | 0.95× | ||
| Q4 25 | — | 0.42× | ||
| Q3 25 | — | 2.89× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.29× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.38× | ||
| Q2 24 | — | 2.11× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
NTAP
| Services | $927.0M | 54% |
| Product | $786.0M | 46% |
